Sign In
Buy CMPX
$1.91
-0.0300 (-1.55%)
At Close: Jul 31, 2026
Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026
10:42am, Friday, 17'th Jul 2026
BOSTON, July 17, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to
Compass Therapeutics: A 50% Price Cut Hiding A Regulatory Mispricing Opportunity
02:31pm, Wednesday, 15'th Jul 2026
Compass Therapeutics is rated Buy, with risk/reward favoring upside after a sharp post-data selloff. CMPX's lead asset, tovecimig, showed strong PFS benefit in BTC, but OS crossover contamination clou
Compass Therapeutics, Inc. (CMPX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
11:12am, Tuesday, 09'th Jun 2026
Compass Therapeutics, Inc. (CMPX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Compass Therapeutics Eyes FDA Path After Tovecimig Trial Win
09:07am, Monday, 08'th Jun 2026
Compass Therapeutics NASDAQ: CMPX Chief Executive Officer Tom Schuetz said the company is preparing for a key U.S. Food and Drug Administration meeting on tovecimig, its DLL4/VEGF bispecific antibody,
Compass Therapeutics to Participate in Upcoming June Investor Events
07:30am, Thursday, 28'th May 2026
BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to t
BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to t
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX
04:00pm, Thursday, 21'st May 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX
03:45pm, Thursday, 21'st May 2026
NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Compass Therapeutics, Inc. ("Compass" or the "Company") (NASDAQ: CMPX). Such investors are advise
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX
06:09pm, Tuesday, 19'th May 2026
NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Compass Therapeutics, Inc. (“Compass” or the “Company”) (NASDAQ: CMPX). Such invest
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX
12:00am, Friday, 15'th May 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX
11:01pm, Thursday, 14'th May 2026
NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Compass Therapeutics, Inc. ("Compass" or the "Company") (NASDAQ: CMPX). Such investors are advi
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX
04:45pm, Tuesday, 12'th May 2026
NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Compass Therapeutics, Inc. (“Compass” or the “Company”) (NASDAQ: CMPX). Such invest
Compass Therapeutics to Participate in Upcoming May Investor Events
07:30am, Tuesday, 12'th May 2026
BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to t
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX
10:00am, Thursday, 07'th May 2026
NEW YORK, May 7, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Compass Therapeutics, Inc. ("Compass" or the "Company") (NASDAQ: CMPX). Such investors are advis
Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update
07:30am, Tuesday, 05'th May 2026
As recently announced, tovecimig (DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel demonstrated a highly statistically significant improvement in progression-free survival (PFS) versu
